Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 119 points (0.7%) at 16,493 as of Wednesday, Jan. 15, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,941 issues advancing vs. 990 declining with 158 unchanged. The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the industry include Alnylam Pharmaceuticals ( ALNY), down 6.3%, Isis Pharmaceuticals ( ISIS), down 4.5%, Incyte ( INCY), down 3.7%, Forest Laboratories ( FRX), down 0.8% and Biogen Idec ( BIIB), down 0.8%. Top gainers within the industry include Intercept Pharmaceuticals ( ICPT), up -1.6%, Pfizer ( PFE), up 0.9% and Amgen ( AMGN), up 0.3%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Valeant Pharmaceuticals International is down $1.90 (-1.4%) to $133.12 on average volume. Thus far, 515,544 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $132.82-$136.20 after having opened the day at $135.08 as compared to the previous trading day's close of $135.01. Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $43.5 billion and is part of the health care sector. Shares are up 15.0% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold. TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.